▶ MAZDUTIDE · SUBTOPIC · DOSING LITERATURE

MAZDUTIDE Dosing Literature

For Laboratory Research Use Only. The content below describes dose ranges as reported in peer-reviewed publications. This page does not recommend any dose for human use. No clinical claim is made. Always consult the original source publication.

SCOPE OF THIS PAGE

This page documents the published-literature dose ranges that appear in trials and animal studies of MAZDUTIDE. Every dose mention is bound to a citation (author, year, PMID where available). The PEPPUDEX wiki phrases these as descriptive observations of the research record, not as instructions to the reader.

ROUTES OF ADMINISTRATION IN PUBLISHED RESEARCH

The published research record for MAZDUTIDE reports the following route(s) of administration: Subcutaneous (Phase 3 clinical). Route selection in a study reflects pharmacokinetic considerations specific to that protocol and is not a recommendation for any human use of MAZDUTIDE.

PHARMACOKINETIC HALF-LIFE

Published pharmacokinetic data report a half-life for MAZDUTIDE of approximately ~7 days (once-weekly). Half-life is the kinetic parameter that frames the dosing rhythm chosen in trial design. It is a measurement, not a recommendation.

CITED DOSE RANGES IN THE LITERATURE

The peer-reviewed sources below report dose ranges, frequencies, and durations used in studies of MAZDUTIDE. Refer to the original publication for full protocol detail.

Zhao H, et al. (2024) reports the MAZDUTIDE protocol used in Mazdutide IBI362 in obese Chinese adults: dose-finding phase 2, published in JAMA Netw Open. See the source for the protocol-level dose range, frequency, and duration. link
Innovent Biologics / Eli Lilly (2024) reports the MAZDUTIDE protocol used in A phase 3 study of mazdutide in Chinese participants with overweight or obesity (GLORY-1), published in ClinicalTrials.gov · Phase 3. NCT05216575. See the source for the protocol-level dose range, frequency, and duration. link

DOSING Q+A FROM LITERATURE

The questions below summarise dosing-relevant entries from the literature record. Each answer is descriptive of published material and is not a recommendation.

▶ What weight loss has Phase 2 shown?

24-week Phase 2 in Chinese adults (Zhao 2024) reported placebo-subtracted weight loss ~11.1% at the 9 mg/wk dose.

▶ Dose in trials?

Phase 2/3 trials titrated subcutaneous 3-9 mg once weekly. This wiki does not recommend any human dose.

STORAGE OF THE REFERENCE COMPOUND

Lyophilized · -20 °C 24 months

Reconstituted · 2-8 °C, 28 days

Storage conditions describe the stability of the research-grade reference material, not a dosing protocol.

RECONSTITUTION MATH (CALCULATOR)

The PEPPUDEX reconstitution calculator at /calculator returns volume-per-dose math given vial mg, BAC mL, and a target dose in mcg. The calculator performs arithmetic only. It does not recommend a dose. Any number entered by a researcher must come from their own protocol design or the cited literature.

REGULATORY CONTEXT

FDA · Investigational outside China. Not FDA-approved.

WADA · Not currently listed on the WADA Prohibited List.

◀ MAZDUTIDE OVERVIEW MECHANISM ▶SAFETY PROFILE ▶

▶ LAST UPDATED · 2026-05-19